Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2017 March ; 26(3): 289–290. doi:10.1158/1055-9965.EPI-17-0006.

Survival deficit for HIV-infected lymphoma patients in the National Cancer Database

Anna E. Coghill¹ and Howard D. Strickler²

¹Division of Cancer Epidemiology and Genetics, National Cancer Institute

²Division of Epidemiology, Albert Einstein College of Medicine

In this issue, Han et.al., report that HIV-infected lymphoma patients experience a survival disadvantage compared to HIV-uninfected lymphoma patients during the era of highly active anti-retroviral therapy (HAART).(1) Despite reductions in the incidence of AIDS-defining malignancies such as non-Hodgkin lymphoma (NHL) with the advent of HAART, the rate of lymphoma amongst HIV-infected individuals remains high compared to the general population. (2–4) Whether HIV-infected patients additionally have worse survival after a lymphoma diagnosis is unclear. As referenced by the authors, clinical trials data suggest that overall mortality for lymphoma patients may be comparable by HIV status. However, population-based data from observational cohort, registry linkage, and healthcare system studies indicate that HIV-related immunosuppression remains an important predictor of mortality after a lymphoma diagnosis. (5–7)

Here the authors compare overall mortality between HIV-infected and HIV-uninfected lymphoma patients using the National Cancer Database, a nationwide hospital-based registry jointly sponsored by the American Cancer Society and the American College of Surgeons. This nationally-representative study included 179,520 lymphoma patients diagnosed from 2004–2011. The large sample size afforded a rare opportunity to measure survival by histologic subtype: Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, and peripheral T-cell lymphoma. Follicular lymphoma (FL) was included as a “control”, a common NHL with no strong HIV association. Approximately 79% of patients had 3 years of complete follow-up. Furthermore, the authors used propensity score matching to efficiently adjust for critical covariates including health insurance status, presence of B-symptoms, comorbidities, tumor stage, and cancer treatment. In short, this study had a number of strengths, with a very large sample size relative to previous studies.

The authors report that HIV-infected lymphoma patients experienced poorer survival than HIV-uninfected lymphoma patients. Notably, this survival deficit was observed for all histologic subtypes assessed, with hazard ratios (HR) indicating an increased risk of overall mortality in HIV-infected lymphoma patients ranging from 1.43 to 1.95. Higher mortality was also observed after attempts to control for confounding by factors such as tumor stage and health insurance status and remained after restriction to lymphoma patients who received chemotherapy (HR range: 1.31–1.86). However, survival in FL cases was no longer

Disclosures. No authors report any conflicts of interest.

significantly associated with HIV status amongst those who received chemotherapy – consistent with the use of FL as a control tumor.

Despite its strengths, this study also had limitations. Chief among these was the exclusive use of overall rather than cancer-specific mortality, especially given concerns regarding competing risks in HIV-infected patients (e.g., death due to other causes),⁽⁸⁾ which were compounded in the current investigation by lack of patient-level CD4+ T-cell data. There was also limited information regarding important prognostic factors such as number of nodal sites affected or extent of abdominal involvement, and future work should include more detailed cancer treatment data (e.g., specific chemotherapy regimens). The authors do note these limitations and correctly conclude, based upon this report and previous population-based studies, that HIV plays a role in determining a patient's outcome after their lymphoma diagnosis.

When considered alongside previous reports of HIV-associated survival deficits for other common tumors (e.g., lung cancer) and randomized trial data demonstrating improved cancer patient survival after the administration of immune-based therapies, ^(9–14) the evidence suggests that immunosuppression plays a fundamental role in cancer progression. Mechanisms underlying the HIV-associated survival deficit reported here likely include both uncontrolled immune activation/inflammation and the depletion of functional T-cells to impede tumor growth. Future studies that could shed light on this association include the correlation of detailed immunological metrics (e.g., CD4/8 T-cell counts) with specific clinical outcomes (e.g., response to chemotherapy). Although such research is often hampered by the lack of longitudinal CD4/8 T-cell measures in a large sample of either HIV-infected or HIV-uninfected cancer patients, longer-term follow-up of clinical cohorts could provide the data to evaluate the degree to which immunosuppression is important for cancer patient outcomes.

References

1. Han X, Jemal A, Hulland E, et al. HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy. *Cancer Epidemiol Biomarkers Prev.* 2016
2. Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. *AIDS.* 2014; 28(6):881–90. [PubMed: 24300545]
3. Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA. Excess cancers among HIV-infected people in the United States. *J Natl Cancer Inst.* 2015; 107(4)
4. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. *Aids.* 2006; 20(12):1645–54. [PubMed: 16868446]
5. Coghill A, Shiels MS, Suneja G, Engels EA. Elevated Cancer-specific Mortality among HIV-infected Persons in the US. *Journal of Clinical Oncology.* 2015 In Press.
6. Chao C, Xu L, Abrams D, et al. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. *AIDS.* 2010; 24(11):1765–70. [PubMed: 20453630]
7. Gopal S, Patel MR, Yanik EL, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. *J Natl Cancer Inst.* 2013; 105(16):1221–9. [PubMed: 23892362]
8. Coghill AE, Shiels MS, Suneja G, Engels EA. Reply to L. Dal Maso et al. *J Clin Oncol.* 2016; 34(4):390–1. [PubMed: 26598741]

9. Suneja G, Shiels MS, Melville SK, Williams MA, Rengan R, Engels EA. Disparities in the treatment and outcomes of lung cancer among HIV-infected people in Texas. *Aids*. 2012
10. Sigel K, Crothers K, Dubrow R, et al. Prognosis in HIV-infected patients with non-small cell lung cancer. *Br J Cancer*. 2013; 109(7):1974–80. [PubMed: 24022194]
11. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010; 363(8):711–23. [PubMed: 20525992]
12. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med*. 2015; 372(4):320–30. [PubMed: 25399552]
13. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. *J Clin Oncol*. 2015
14. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*. 2012; 366(26):2443–54. [PubMed: 22658127]